NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.56 +0.54 (+2.84 %) (As of 02/17/2019 11:09 AM ET)Previous Close$19.56Today's Range$19.06 - $19.7352-Week Range$12.04 - $25.00Volume74,657 shsAverage Volume49,566 shsMarket Capitalization$359.85 millionP/E Ratio-10.99Dividend YieldN/ABeta2.91 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing; and Novartis to manufacture and supply the CAR-T cell therapy KymriahÂ. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York. Receive CBMG News and Ratings via Email Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBMG Previous Symbol CUSIPN/A Webwww.cellbiomedgroup.com Phone408-973-7884Debt Debt-to-Equity RatioN/A Current Ratio11.86 Quick Ratio11.86Price-To-Earnings Trailing P/E Ratio-10.99 Forward P/E Ratio-9.59 P/E GrowthN/A Sales & Book Value Annual Sales$340,000.00 Price / Sales1,058.37 Cash FlowN/A Price / Cash FlowN/A Book Value$3.77 per share Price / Book5.19Profitability EPS (Most Recent Fiscal Year)($1.78) Net Income$-25,490,000.00 Net Margins-13,988.39% Return on Equity-44.62% Return on Assets-41.84%Miscellaneous Employees125 Outstanding Shares18,397,000Market Cap$359.85 million OptionableOptionable Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions What is Cellular Biomedicine Group's stock symbol? Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG." How will Cellular Biomedicine Group's stock buyback program work? Cellular Biomedicine Group declared that its Board of Directors has initiated a stock repurchase program on Sunday, June 4th 2017, which permits the company to buyback $10,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company's board believes its stock is undervalued. How were Cellular Biomedicine Group's earnings last quarter? Cellular Biomedicine Group Inc (NASDAQ:CBMG) posted its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.04. The biotechnology company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Cellular Biomedicine Group had a negative net margin of 13,988.39% and a negative return on equity of 44.62%. View Cellular Biomedicine Group's Earnings History. When is Cellular Biomedicine Group's next earnings date? Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Cellular Biomedicine Group. What price target have analysts set for CBMG? 3 Wall Street analysts have issued 12 month price objectives for Cellular Biomedicine Group's stock. Their forecasts range from $26.00 to $38.00. On average, they anticipate Cellular Biomedicine Group's share price to reach $32.00 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group. What is the consensus analysts' recommendation for Cellular Biomedicine Group? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group. Has Cellular Biomedicine Group been receiving favorable news coverage? Media stories about CBMG stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cellular Biomedicine Group earned a daily sentiment score of -2.8 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of Cellular Biomedicine Group's key competitors? Some companies that are related to Cellular Biomedicine Group include Alector (ALEC), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Coherus Biosciences (CHRS), Editas Medicine (EDIT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Vericel (VCEL), Novavax (NVAX) and BAVARIAN NORDIC/S (BVNRY). Who are Cellular Biomedicine Group's key executives? Cellular Biomedicine Group's management team includes the folowing people: Mr. Bizuo Liu, CEO, CFO & Director (Age 54)Dr. Yihong Yao, Chief Scientific Officer (Age 51)Mr. Andrew K. Chan, Sr. VP of Corp. Bus. Devel., Sec. & Chief Legal Officer (Age 61)Dr. Xia Meng Ph.D., BS, Gen. Mang. of Early Diagnosis & InterventionDerrick C. Li, Head of Strategy & Investor Relations Who are Cellular Biomedicine Group's major shareholders? Cellular Biomedicine Group's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.58%), Northern Trust Corp (0.88%), Geode Capital Management LLC (0.69%), Bank of New York Mellon Corp (0.21%), Rhumbline Advisers (0.08%) and Bank of America Corp DE (0.06%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group. Which institutional investors are selling Cellular Biomedicine Group stock? CBMG stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp. View Insider Buying and Selling for Cellular Biomedicine Group. Which institutional investors are buying Cellular Biomedicine Group stock? CBMG stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Bank of America Corp DE, MetLife Investment Advisors LLC, Bank of New York Mellon Corp, Rhumbline Advisers, Metropolitan Life Insurance Co. NY and Meeder Asset Management Inc.. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group. How do I buy shares of Cellular Biomedicine Group? Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cellular Biomedicine Group's stock price today? One share of CBMG stock can currently be purchased for approximately $19.56. How big of a company is Cellular Biomedicine Group? Cellular Biomedicine Group has a market capitalization of $359.85 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-25,490,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. Cellular Biomedicine Group employs 125 workers across the globe. What is Cellular Biomedicine Group's official website? The official website for Cellular Biomedicine Group is http://www.cellbiomedgroup.com. How can I contact Cellular Biomedicine Group? Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected] MarketBeat Community Rating for Cellular Biomedicine Group (NASDAQ CBMG)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 126 (Vote Outperform)Underperform Votes: 137 (Vote Underperform)Total Votes: 263MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe CBMG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2019 by MarketBeat.com StaffFeatured Article: Are all No-Load Funds Equal?